Y-mAbs Therapeutics, Inc. (YMAB)

Market Cap	498.95M
Revenue (ttm)	84.50M
Net Income (ttm)	-21.67M
Shares Out	43.88M
EPS (ttm)	-0.49
PE Ratio	n/a
Forward PE	119.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	371,047
Open	11.66
Previous Close	11.83
Day's Range	11.16 - 11.79
52-Week Range	4.60 - 20.90
Beta	0.68
Analysts	Buy
Price Target	18.43 (+62.09%)
Earnings Date	Aug 8, 2024

About YMAB

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line r...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 21, 2018
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: YMAB

Financial Performance

In 2023, YMAB's revenue was $84.82 million, an increase of 29.96% compared to the previous year's $65.27 million. Losses were -$21.43 million, -77.58% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for YMAB stock is "Buy." The 12-month stock price forecast is $18.43, which is an increase of 62.09% from the latest price.

Price Target

$18.43

(62.09% upside)

Analyst Consensus: Buy